EN DE
Watch Suven Life Sciences Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Suven Life Sciences Limited (SUVEN) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Suven Life Sciences Limited stock ₹130, price ₹280, that is 53.5% below the price, quality 32 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE495B01020

SL Suven Life Sciences Limited logo Thin data Nov 10, 2026

Suven Life Sciences Limited

SUVEN · NSE
Very expensive, weak quality

Our calculation puts a fair price 53% below what the stock costs today.

Low debt
Revenue last quarter +91% vs. a year ago.
Fair value ₹130.30 · Strongly overvalued
Quality 32/100
Weak Growth (revenue 5y −12.0 %/yr in INR)
Negative free cash flow
Trails peers (2/7)
Narrow moat 9/100
Thin data
Estimate
Watch Suven Life Sciences Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹392.00 ₹45.65 Fair Value ₹130.30 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range ₹45.65 – ₹392.00 · fair‑value band ₹97.73 – ₹162.88 · the ₹279.95 price screens above the ₹130.30 fair value. As of Nov 10, 2026.

Follow Suven Life Sciences in your weekly email

Every Wednesday you see whether Suven Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally.

Show moreShow less

The company engages in drug discovery and development of new chemical entities in central nervous system diseases.

Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders.

The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for treating gastrointestinal disorders.

The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India.

Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.

Stock analysis

Suven Life Sciences Limited (SUVEN) currently trades at ₹279.95, while our estimate is ₹130.30, 53% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₹97.73 (bear) to ₹162.88 (bull), the price of ₹279.95 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Suven Life Sciences Limited reported revenue of ₹71.1M in FY2026 versus ₹118M in FY2022, a compound −12.0%/yr. Reported net income was −₹2.8B in FY2026.

Key figures

Market cap ₹82.5B (≈ $878M) Small · EPS (TTM) ₹−14.89 · Return on equity −78.8% · Return on assets (EBIT) −73.4% (5-year average) · Operating margin −3,776% · Revenue (TTM) ₹88.1M · Revenue growth (YoY) +91.0% · EPS growth (YoY) +15.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 29% below its 52-week high and 122% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −53%, SUVEN screens richer than that median.

Fair Value

Bear ₹97.73 Fair Value ₹130.30 Bull ₹162.88
Price ₹279.95 · Downside -53.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 11
Does it invest with discipline instead of growing at any price?
Low Volatility 33
How calm the share price moves, does not count
Price momentum 68
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 73
Distance to the 52-week high, does not count
New shares 19
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.0%
Start year 2021 (pandemic). Over 10 years: −34.6% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−622.3% (2021) → −4,077.7% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

SUVEN screens overvalued: fair value 53% below the price. Compare with Merck KGaA →

Compare Suven Life Sciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −53.5% · Bottom 25%
Profitability
Return on assets −44.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 91.0% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 13.94× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs SUVEN
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs SUVEN
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs SUVEN
Haleon plc HLN $9.06 $8.62 −5% vs SUVEN
Merck KGaA MRK €149.35 €109.18 −27% vs SUVEN
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs SUVEN
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs SUVEN
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs SUVEN
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs SUVEN
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs SUVEN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Suven Life Sciences Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Suven Life Sciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/SUVEN

Frequently asked questions

Is Suven Life Sciences Limited (SUVEN) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is ₹130.30 versus a price of ₹279.95, about 53% lower (overvalued).
What is the fair value of SUVEN?
Our estimate for Suven Life Sciences Limited is ₹130.30 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹279.95.
What is the quality score of SUVEN?
Suven Life Sciences Limited has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Suven Life Sciences Limited (SUVEN)?
Our calculated price target is the estimate of ₹130.30 (as of Nov 10, 2026). Cautious scenario ₹97.73, optimistic scenario ₹162.88. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Suven Life Sciences Limited stock forecast for 2026?
Our estimate puts fair value at ₹130.30, about 53% lower versus a price of ₹279.95 (overvalued). Cautious scenario ₹97.73, optimistic scenario ₹162.88. The calculation is refreshed regularly with new filings.
What is the revenue of Suven Life Sciences Limited (SUVEN)?
Suven Life Sciences Limited reported trailing-twelve-month revenue of about ₹88.1M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Suven Life Sciences Limited (SUVEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Suven Life Sciences Limited it is ₹130.30 per share (as of Nov 10, 2026), against a price of ₹279.95.
Is Suven Life Sciences Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SUVEN trades above its calculated fair value: price ₹279.95, fair value ₹130.30, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SUVEN?
No. The price is what the market pays today (₹279.95); the fair value is what the company's own numbers justify (₹130.30). For Suven Life Sciences Limited the two are ₹149.65 per share apart. That gap is exactly why we show both numbers side by side.
How much is Suven Life Sciences Limited worth?
The market values Suven Life Sciences Limited at about ₹82.5B (market capitalisation, as of Nov 10, 2026). Per share that is ₹279.95; our models calculate a fair value of ₹130.30 per share.
What do the bullish and bearish scenarios say about SUVEN?
Our models span a range for Suven Life Sciences Limited: cautious scenario ₹97.73, base ₹130.30, optimistic ₹162.88 per share (as of Nov 10, 2026, price ₹279.95). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Suven Life Sciences Limited (SUVEN)?
Balance-sheet figures for Suven Life Sciences Limited (as of Nov 10, 2026): return on equity −78.8%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is SUVEN from its 52-week high?
Suven Life Sciences Limited trades at ₹279.95, about 29% below its 52-week high of ₹392.00 and 122% above the low of ₹126.22 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹130.30 is for.
Which stocks are comparable to Suven Life Sciences Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Suven Life Sciences Limited stock attractive at the current price?
The data as of Nov 10, 2026: price ₹279.95, calculated fair value ₹130.30 (−53%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Suven Life Sciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Suven Life Sciences Limited (SUVEN)?
The closing price on Nov 9, 2026 was ₹279.95. Our estimate is ₹130.30, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Suven Life Sciences Limited right now?
The price sits above even our optimistic bull case (₹162.88). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Suven Life Sciences Limited

How large is the market capitalisation of Suven Life Sciences Limited (SUVEN)?
The market capitalisation of Suven Life Sciences Limited is ₹82.5B (≈ $878M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Suven Life Sciences Limited (SUVEN)?
Earnings per share at Suven Life Sciences Limited are ₹−14.89. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Suven Life Sciences Limited (SUVEN)?
The return on equity (ROE) of Suven Life Sciences Limited is −78.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Suven Life Sciences Limited (SUVEN)?
On an EBIT basis the return on assets of Suven Life Sciences Limited is −73.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Suven Life Sciences Limited (SUVEN)?
The operating margin of Suven Life Sciences Limited is −3,776% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Suven Life Sciences Limited (SUVEN)?
Revenue at Suven Life Sciences Limited is growing +91.0% versus a year earlier (3y avg −19.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Suven Life Sciences Limited (SUVEN)?
Earnings per share at Suven Life Sciences Limited are growing +15.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Suven Life Sciences Limited (SUVEN) generate?
The free cash flow of Suven Life Sciences Limited is −₹3.0B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Suven Life Sciences Limited (SUVEN) hold?
Suven Life Sciences Limited holds more cash than debt, ₹3.2B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Suven Life Sciences Limited in the live analysis

One click puts Suven Life Sciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.